Podcast Episodes
Back to Search
Episode 396: Uromigos Japan - 激論 @JSMO25
尿路上皮癌と腎癌の臨床に影響を与えるエビデンスをどう解釈するか!?
1 year, 7 months ago
Episode 395: Uromigos Japan: ASCO GU 2025のレビュー
ASCOGU2025で発表された臨床試験の結果の解釈について忖度なしに議論しました！！
1 year, 8 months ago
Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025
Tyler Seibert from UCSD joins the show live from Lugano to discuss meeting highlights and controversies (and his favorite run along the water..)
1 year, 8 months ago
Episode 393: ASCO GU 2025 Review Podcast
Silke joins Tom and Brian to discuss highlights form ASCO GU 2025
1 year, 8 months ago
Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC
Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
1 year, 8 months ago
Episode 391: ASCO GU 2025 - KIM-1 Data from Checkmate 214
Vincent Xu discusses this emerging RCC biomarker and data from the Checkmate 214 trial
1 year, 8 months ago
Episode 390: ASCO GU 2025 - Pembro-based Doublets in Refractory RCC and COSMIC-313 OS Update
Laurence Albiges joins the show to discuss novel combos in refractory RCC and an update of the Ipi/Nivo/Cabo COSMIC OS data
1 year, 8 months ago
Episode 388: ASCO GU 2025 - FGF3 Inhibition with LOXO-435 in Urothelial Cancer
Gopa Iyer from MSKCC joins the show to discuss his initial results from this phase 2 trial.
1 year, 8 months ago
Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results
Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins us t…
1 year, 8 months ago
Episode 389: ASCO GU 2025 - NIAGARA Pathologic CR Updates and Outcomes
Matt Galsky joins the show to discuss pCR in NIAGARA and clinical implications.
1 year, 8 months ago